ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders


This invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA, to be followed by a Phase I clinical trial planned for 2017. Disorders amenable to treatment with the peptides include hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, HDL deficiency, hypertriglyceridemia, apoA-I deficiency, acute coronary syndrome, angina pectoris, aortic valve stenosis, atherosclerosis, carotid atherosclerosis, congestive heart failure, cerebral stroke, coronary artery disease, inflammation of the cardiovascular system, intermittent claudication, myocardial infarction, peripheral vascular disease, post-ischemic reperfusion, renal artery stenosis, reperfusion myocardial injury, restenosis, and thrombotic stroke.

Potential Commercial Applications: Competitive Advantages:
  • Treatment and prevention of many hereditary, chronic and acute dyslipidemic and vascular disorders, where other treatments are not effective or too invasive, such as statins, partial ileal bypass surgery, portacaval shunt, liver transplantation, and removal of atherogenic lipoproteins by one of several apheresis procedures.
  • Also applicable to the treatment of inflammation, asthma, colitis, inflammatory bowel disease (IBD), chronic kidney disease (CKD).
 


Inventors:

Alan Remaley (NHLBI)  ➽ more inventions...

Stephen Demosky (NHLBI)  ➽ more inventions...

John Stonik (NHLBI)  ➽ more inventions...

Marcelo Amar (NHLBI)  ➽ more inventions...

Edward Neufeld (NHLBI)  ➽ more inventions...

Fairwell Thomas (NHLBI)  ➽ more inventions...

H. Bryan Brewer (NHLBI)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,572,771 issued 2009-08-11
U.S. Pat: 8,071,746 issued 2011-12-06
U.S. Pat: 8,148,323 issued 2012-04-03
U.S. Pat: 8,835,378 issued 2014-09-16
US Application No. 12/766,761
US Application No. 13/407,132
Various international patents issued

Publications:
Sethi AA, et al. PMID 18805791
D'Souza W, et al. PMID 20508181
Jin X, et al. PMID 27758769
Nowacki TM, et al. PMID 27425846
Yao X, et al. PMID 21115733
Osei-Hwedieh DO, et al. PMID 21172387
Yao X, et al. PMID 27327118
Souza AC, et al. PMID 26994575
Schwendeman A, et al. PMID 26117661
Sviridov DO, et al. PMID 23042953
Dai C, et al. PMID 22427535
Tabet F, et al. PMID 19965776
Amar MJ, et al. PMID 20484557

Collaboration Opportunity:

The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize ApoA-1 mimetic peptides. For collaboration opportunities, please contact Denise Crooks, Ph.D. at 301-435-0103 or crooksd@nhlbi.nih.gov.


Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-114-2004-0
Updated: Nov 29, 2016